The Evolving Treatment Paradigm for Diffuse Large B-Cell Lymphoma December 20, 2023B Cell LymphomaMantle Cell Lymphoma
Commentary: Bendamustine, PET/CT Biomarkers, and BTKi in B-Cell Lymphoma, December 2023December 11, 2023B Cell Lymphoma
Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR TDecember 11, 2023DLBCLB Cell Lymphoma
FDA approves pirtobrutinib for previously treated CLL/SLLDecember 4, 2023CLLMantle Cell LymphomaB Cell Lymphoma
Combination of time-limited ibrutinib and chimeric antigen receptor T-cells shows promise in r/r MCLNovember 15, 2023B Cell Lymphoma
Axi-cel vs tisagenlecleucel improves efficacy but may cause higher neurologic toxicity in LBCLNovember 15, 2023B Cell Lymphoma
No benefit of ASCT over radioimmunotherapy in R/R FL in the rituximab ageNovember 15, 2023B Cell Lymphoma
TP53 mutations predict inferior outcomes in newly diagnosed aggressive BCLNovember 15, 2023B Cell Lymphoma
Allogeneic HSCT offers a salvage treatment option for chemo-susceptible relapsed or refractory DLBCLNovember 15, 2023B Cell Lymphoma
Ibrutinib-venetoclax tops chlorambucil-obinutuzumab in treatment-naïve CLL over a 4-year follow-upNovember 15, 2023B Cell Lymphoma
Preapheresis bendamustine worsens CAR T-cell therapy outcomes in relapsed or refractory LBCLNovember 15, 2023B Cell Lymphoma
Commentary: Recent Practice-Changing Studies in LBCL and MCL, November 2023November 1, 2023B Cell Lymphoma
